Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The solvency position, as indicated by the provided ratios, demonstrates a generally strengthening financial structure over the analyzed period spanning from March 2022 to December 2025. A consistent pattern of decreasing leverage is observed alongside improving coverage of interest obligations. These trends suggest a reduced reliance on debt financing and an enhanced ability to meet financial commitments.
- Debt Ratios (Debt to Equity, Debt to Capital, Debt to Assets)
- A clear downward trend is evident across all three debt ratios. Debt to equity decreased steadily from 0.14 in March 2022 to 0.09 by December 2025. Similarly, debt to capital declined from 0.12 to 0.08 over the same period. Debt to assets followed this pattern, moving from 0.10 to 0.07. This consistent reduction indicates a decreasing proportion of debt relative to equity, capital, and total assets, signifying a more conservative capital structure.
- Financial Leverage
- Financial leverage exhibited a slight initial decrease from 1.32 in March 2022 to 1.27 in December 2022, followed by relative stability, fluctuating between 1.27 and 1.30 through December 2025. While not a consistent decline like the debt ratios, the leverage ratio remained relatively contained, suggesting a controlled use of financial leverage.
- Interest Coverage
- The interest coverage ratio demonstrated a notable improvement over the period. Starting at 163.24 in March 2022, it experienced a decline through December 2022, reaching 82.80. However, from March 2023 onwards, the ratio consistently increased, culminating in 120.42 by December 2025. This upward trajectory indicates a significantly enhanced ability to cover interest expenses with earnings, bolstering financial safety.
In summary, the observed trends suggest a strengthening solvency position characterized by decreasing debt levels relative to equity and assets, stable financial leverage, and a substantial improvement in the ability to service debt obligations. These factors collectively contribute to a more secure financial foundation.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Finance lease liabilities, current portion | |||||||||||||||||||||
| Long-term debt | |||||||||||||||||||||
| Finance lease liabilities, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio for the analyzed period demonstrates a consistent downward trend, indicating a strengthening financial position with respect to leverage. Throughout the observed timeframe, the ratio decreased from 0.14 to 0.09.
- Total Debt
- Total debt exhibits a modest, incremental increase over the period, rising from 2,700,400 to 2,705,900. This increase is relatively small compared to the growth in stockholders’ equity, suggesting that the company is funding its operations and growth primarily through equity rather than debt.
- Stockholders’ Equity
- Stockholders’ equity shows a substantial and consistent increase, progressing from 19,914,700 to 31,256,900. This growth is indicative of retained earnings, potentially supplemented by new equity issuances, and contributes significantly to the declining debt to equity ratio.
- Debt to Equity Ratio Trend
- The initial value of 0.14 in March 2022 decreased to 0.13 by June 2022, and continued to decline gradually to 0.10 by December 2023. The ratio stabilized at 0.09 from September 2024 through December 2025. This consistent reduction suggests a decreasing reliance on debt financing and an improved ability to cover obligations with equity. The rate of decline slowed over time, but the overall trend remains firmly downward.
The observed trend suggests a decreasing financial risk profile. A lower debt to equity ratio generally indicates a greater capacity to absorb losses and a stronger financial foundation. The consistent growth in equity, coupled with relatively stable debt levels, supports this interpretation.
Debt to Capital
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Finance lease liabilities, current portion | |||||||||||||||||||||
| Long-term debt | |||||||||||||||||||||
| Finance lease liabilities, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||
| Total capital | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio for the analyzed period demonstrates a consistent downward trend, indicating a strengthening solvency position. Throughout the observed timeframe, the ratio decreased from 0.12 to 0.08, suggesting a decreasing reliance on debt financing relative to the company’s total capital structure.
- Total Debt
- Total debt exhibits a modest, consistent increase over the period, rising from US$2,700.4 million to US$2,705.9 million. This incremental increase suggests a controlled approach to debt accumulation.
- Total Capital
- Total capital demonstrates a substantial and consistent increase throughout the period, growing from US$22,615.1 million to US$33,962.8 million. This growth significantly outpaces the increase in total debt, driving the observed decline in the debt to capital ratio.
- Debt to Capital Ratio – Trend Analysis
- The ratio began at 0.12 in March 2022 and gradually decreased to 0.08 by December 2025. The most significant declines occurred between September 2022 and December 2023, and then stabilized between September 2024 and December 2025. This consistent reduction suggests improved financial leverage and a lower risk profile associated with debt obligations.
The observed trend indicates that the company is increasingly financing its operations and growth through equity or retained earnings rather than debt. This shift could be viewed favorably by investors and credit rating agencies, as it suggests a more sustainable and less risky financial structure.
Debt to Assets
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Finance lease liabilities, current portion | |||||||||||||||||||||
| Long-term debt | |||||||||||||||||||||
| Finance lease liabilities, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt to assets ratio for the analyzed period demonstrates a consistent, albeit gradual, decline. Initially, the ratio remained stable at 0.10 for the first three quarters of 2022. Subsequently, a downward trend commenced, continuing through the observed timeframe.
- Debt to Assets Ratio Trend
- From a value of 0.10 in the first three quarters of 2022, the ratio decreased to 0.09 for the entirety of 2023. This decline continued into 2024, reaching 0.07 and remaining constant through the final observation in the first half of 2025.
The consistent decrease in the debt to assets ratio suggests a strengthening of the company’s financial position over the analyzed period. This could be attributed to an increase in total assets at a rate exceeding that of total debt, or a reduction in total debt, or a combination of both. The observed pattern indicates a diminishing reliance on debt financing relative to the company’s asset base.
- Total Debt
- Total debt exhibited a modest, consistent increase throughout the period, rising from US$2,700.4 million in March 2022 to US$2,705.9 million in December 2025. The increases were incremental, suggesting a controlled approach to debt accumulation.
- Total Assets
- Total assets experienced a more substantial and consistent increase, growing from US$26,348.7 million in March 2022 to US$40,558.7 million in December 2025. This growth significantly outpaced the increase in total debt, contributing to the observed decline in the debt to assets ratio.
The combination of relatively stable debt levels and increasing asset values indicates improving solvency. The company appears to be effectively utilizing its assets to fund operations and growth, reducing its dependence on debt financing. The consistent downward trend in the ratio suggests a reduced financial risk profile.
Financial Leverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial leverage ratio for the analyzed period demonstrates a generally stable profile, with minor fluctuations. Overall, the company maintains a moderate level of financial leverage, indicating a reliance on debt financing that remains relatively consistent over the observed timeframe.
- Trend Analysis
- The financial leverage ratio began at 1.32 in March 2022 and remained at that level through June 2022. A slight decrease to 1.29 was observed in September 2022, holding steady through December 2022. The ratio continued to decline modestly to 1.28 by March 2023, remaining consistent through June 2023. A slight increase to 1.29 occurred in September 2023, followed by a decrease to 1.27 in December 2023. The ratio stabilized around 1.28 for the first half of 2024, before increasing to 1.29 in September 2024. It remained relatively stable through December 2024, and then increased to 1.30 in both September and December 2025.
- Magnitude and Stability
- Throughout the majority of the period, the financial leverage ratio remained within a narrow band between 1.27 and 1.32. This suggests a consistent approach to capital structure management. The recent increase to 1.30 in the final two quarters indicates a slight increase in the proportion of assets financed by debt, but remains within a reasonable range.
- Asset and Equity Relationship
- Total assets increased consistently over the period, from US$26,348.7 million in March 2022 to US$40,558.7 million in December 2025. Stockholders’ equity also increased, from US$19,914.7 million to US$31,256.9 million over the same period. The relatively stable financial leverage ratio indicates that the growth in assets and equity has been broadly proportional, maintaining the company’s debt-to-equity profile.
In conclusion, the financial leverage ratio exhibits a pattern of stability with minor fluctuations, suggesting a controlled and consistent financial strategy. The recent slight increase warrants continued monitoring, but does not currently indicate a significant shift in the company’s risk profile.
Interest Coverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Net income | |||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Interest coverage
= (EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025
+ EBITQ1 2025)
÷ (Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025
+ Interest expenseQ1 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The interest coverage ratio exhibits considerable fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrates a strong position, but a clear downward trend emerges before stabilizing and then increasing again.
- Initial Strength and Decline (Mar 31, 2022 – Dec 31, 2022)
- The interest coverage ratio begins at a high of 163.24 in March 2022, indicating a substantial ability to meet interest obligations. However, a consistent decline is observed through the end of 2022, falling to 82.80. This decrease suggests a weakening capacity to cover interest expenses, potentially due to decreasing earnings or increasing interest expense, or a combination of both.
- Continued Weakness and Stabilization (Mar 31, 2023 – Dec 31, 2023)
- The downward trend continues into the first half of 2023, reaching a low of 58.52 in September 2023. While still above one, this level represents a significantly reduced margin of safety. The ratio then shows a slight stabilization, increasing to 69.47 by March 2024, suggesting a potential bottoming out of the decline.
- Recovery and Fluctuations (Mar 31, 2024 – Dec 31, 2025)
- From March 2024 onwards, the interest coverage ratio demonstrates a recovery, peaking at 134.19 in June 2025. This improvement is likely driven by increased earnings. However, the ratio experiences a decline in September 2025, followed by a slight increase in December 2025, settling at 120.42. This final period indicates continued, but fluctuating, ability to cover interest obligations.
Overall, the period is characterized by a significant initial decline in the interest coverage ratio, followed by a period of stabilization and eventual recovery. The fluctuations in the later part of the period suggest sensitivity to changes in earnings and/or interest expense. While the ratio remains above one throughout the entire period, the observed volatility warrants continued monitoring.